Leukemia Research
Volume 27, Issue 5 , Pages 445-453 , May 2003

Inactivation of deoxycytidine kinase and overexpression of P-glycoprotein in AraC and daunorubicin double resistant leukemic cell lines

Received 18 March 2002 ,Accepted 28 September 2002.

References 

  1. Hiddemann W. Cytosine arabinoside in the treatment of acute myeloid leukemia: the role and place of high-dose regimens. Ann Hematol. 1999;62:119–128
  2. Schiller GJ. Treatment of resistant disease. Leukemia. 1998;12(Suppl 1):S20–S24
  3. Rowe JM. What is the best induction regimen for acute myelogenous leukemia?. Leukemia. 1998;12(Suppl 1):S16–S19
  4. Marie JP, Zhou DC, Gurbuxani S, Legrand O, Zittoun R. MDR1/P-glycoprotein in haematological neoplasms. Eur J Cancer. 1996;32A:1034–1038
  5. Beck WT. The cell biology of multiple drug resistance. Biochem Pharmacol. 1987;36:2879–2887
  6. Cole SP, Bhardwaj G, Gerlach JH, Mackie JE, Grant CE, Almquist KC, et al.  Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science. 1992;258:1650–1654
  7. Zaman GJ, Flens MJ, van Leusden MR, de Haas M, Mulder HS, Lankelma J, et al.  The human multidrug resistance-associated protein MRP is a plasma membrane drug-efflux pump. Proc Natl Acad Sci USA. 1994;91:8822–8826
  8. Scheper RJ, Broxterman HJ, Scheffer GL, Kaaijk P, Dalton WS, van Heijningen TH, et al.  Overexpression of a M(r) 110,000 vesicular protein in non-P-glycoprotein-mediated multidrug resistance. Cancer Res. 1993;53:1475–1479
  9. Chen YN, Mickley LA, Schwartz AM, Acton EM, Hwang JL, Fojo AT. Characterization of adriamycin-resistant human breast cancer cells which display overexpression of a novel resistance-related membrane protein. J Biol Chem. 1990;265:10073–10080
  10. Doyle LA, Yang W, Abruzzo LV, Krogmann T, Gao Y, Rishi AK, et al.  A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc Natl Acad Sci USA. 1998;95:15665–15670
  11. Ross DD, Karp JE, Chen TT, Doyle LA. Expression of breast cancer resistance protein in blast cells from patients with acute leukemia. Blood. 2000;96:365–368
  12. Feller N, Kuiper CM, Lankelma J, Ruhdal JK, Scheper RJ, Pinedo HM, et al.  Functional detection of MDR1/P170 and MRP/P190-mediated multidrug resistance in tumour cells by flow cytometry. Br J Cancer. 1995;72:543–549
  13. Ross DD, Wooten PJ, Sridhara R, Ordonez JV, Lee EJ, Schiffer CA. Enhancement of daunorubicin accumulation, retention, and cytotoxicity by verapamil or cyclosporin A in blast cells from patients with previously untreated acute myeloid leukemia. Blood. 1993;82:1288–1299
  14. Ino T, Miyazaki H, Isogai M, Nomura T, Tsuzuki M, Tsuruo T, et al.  Expression of P-glycoprotein in de novo acute myelogenous leukemia at initial diagnosis: results of molecular and functional assays, and correlation with treatment outcome. Leukemia. 1994;8:1492–1497
  15. Schneider E, Cowan KH, Bader H, Toomey S, Schwartz GN, Karp JE, et al.  Increased expression of the multidrug resistance-associated protein gene in relapsed acute leukemia. Blood. 1995;85:186–193
  16. Zhou DC, Zittoun R, Marie JP. Expression of multidrug resistance-associated protein (MRP) and multidrug resistance (MDR1) genes in acute myeloid leukemia. Leukemia. 1995;9:1661–1666
  17. Del Poeta G, Venditti A, Aronica G, Stasi R, Cox MC, Buccisano F, et al.  P-glycoprotein expression in de novo acute myeloid leukemia. Leuk Lymphoma. 1997;27:257–274
  18. Broxterman HJ, Sonneveld P, Pieters R, Lankelma J, Eekman CA, Loonen AH, et al.  Do P-glycoprotein and major vault protein (MVP/LRP) expression correlate with in vitro daunorubicin resistance in acute myeloid leukemia?. Leukemia. 1999;13:258–265
  19. Filipits M, Stranzl T, Pohl G, Suchomel RW, Zochbauer S, Brunner R, et al.  MRP expression in acute myeloid leukemia. An update. Adv Exp Med Biol. 1999;457:141–150
  20. Owens JK, Shewach DS, Ullman B, Mitchell BS. Resistance to 1-beta-D-arabinofuranosylcytosine in human T-lymphoblasts mediated by mutations within the deoxycytidine kinase gene. Cancer Res. 1992;52:2389–2393
  21. Ruiz van Haperen V, Veerman G, Eriksson S, Boven E, Stegmann AP, Hermsen M, et al.  Development and molecular characterization of a 2′,2′-difluorodeoxycytidine-resistant variant of the human ovarian carcinoma cell line A2780. Cancer Res. 1994;54:4138–4143
  22. Bhalla K, Nayak R, Grant S. Isolation and characterization of a deoxycytidine kinase- deficient human promyelocytic leukemic cell line highly resistant to 1-beta-D- arabinofuranosylcytosine. Cancer Res. 1984;44:5029–5037
  23. Dumontet C, Fabianowska-Majewska K, Mantincic D, Callet BE, Tigaud I, Gandhi V, et al.  Common resistance mechanisms to deoxynucleoside analogues in variants of the human erythroleukaemic line K562. Br J Haematol. 1999;106:78–85
  24. Kees UR, Ford J, Dawson VM, Piall E, Aherne GW. Development of resistance to 1-beta-D-arabinofuranosylcytosine after high-dose treatment in childhood lymphoblastic leukemia: analysis of resistance mechanism in established cell lines. Cancer Res. 1989;49:3015–3019
  25. Stegmann AP, Honders MW, Hagemeijer A, Hoebee B, Willemze R, Landegent JE. In vitro-induced resistance to the deoxycytidine analogues cytarabine (AraC) and 5-aza-2′-deoxycytidine (DAC) in a rat model for acute myeloid leukemia is mediated by mutations in the deoxycytidine kinase (dck) gene. Ann Hematol. 1995;71:41–47
  26. Stegmann AP, Honders MW, Willemze R, Landegent JE. De novo induced mutations in the deoxycytidine kinase (dck) gene in rat leukemic clonal cell lines confer resistance to cytarabine (AraC) and 5- aza-2′-deoxycytidine (DAC). Leukemia. 1995;9:1032–1038
  27. Flasshove M, Strumberg D, Ayscue L, Mitchell BS, Tirier C, Heit W, et al.  Structural analysis of the deoxycytidine kinase gene in patients with acute myeloid leukemia and resistance to cytosine arabinoside. Leukemia. 1994;8:780–785
  28. Veuger MJT, Honders MW, Landegent JE, Willemze R, Barge RM. High incidence of alternatively spliced forms of deoxycytidine kinase in patients with resistant acute myeloid leukemia. Blood. 2000;96:1517–1524
  29. Veuger MJT, Heemskerk MH, Honders MW, Willemze R, Barge RM. Functional role of alternatively spliced deoxycytidine kinase in sensitivity to cytarabine of acute myeloid leukemic cells. Blood. 2002;99:1373–1380
  30. Belloc F, Cotteret S, Labroille G, Schmit V, Jaloustre C, Dumain P, et al.  Bcr-abl translocation can occur during the induction of multidrug resistance and confers apoptosis resistance on myeloid leukemic cell lines. Cell Death Diff. 1997;4:806–814
  31. Veuger MJT, Honders MW, Landegent JE, Willemze R, Barge RM. A novel RT-PCR-based protein activity truncation assay for direct assessment of deoxycytidine kinase in small numbers of purified leukemic cells. Leukemia. 2000;14:1678–1684
  32. Kartner N, Evernden-Porelle D, Bradley G, Ling V. Detection of P-glycoprotein in multidrug-resistant cell lines by monoclonal antibodies. Nature. 1985;316:820–823
  33. Jonsson K, Dahlberg N, Tidefelt U, Paul C, Andersson G. Characterization of an anthracycline-resistant human promyelocyte leukemia (HL-60) cell line with an elevated MDR-1 gene expression. Biochem Pharmacol. 1995;49:755–762
  34. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976;72:248–254
  35. Leith CP, Kopecky KJ, Chen IM, Eijdems L, Slovak ML, McConnell TS, et al.  Frequency and clinical significance of the expression of the multidrug resistance proteins MDR1/P-glycoprotein, MRP1, and LRP in acute myeloid leukemia: a Southwest Oncology Group Study. Blood. 1999;94:1086–1099
  36. Versantvoort CH, Broxterman HJ, Bagrij T, Scheper RJ, Twentyman PR. Regulation by glutathione of drug transport in multidrug-resistant human lung tumour cell lines overexpressing multidrug resistance-associated protein. Br J Cancer. 1995;72:82–89
  37. Grant S, Turner A, Nelms P, Yanovich S. Characterization of a multidrug resistant human erythroleukemia cell line (K562) exhibiting spontaneous resistance to 1-beta-D- arabinofuranosylcytosine. Leukemia. 1995;9:808–814
  38. Martin-Aragon S, Mukherjee SK, Taylor BJ, Ivy SP, Fu CH, Ardi VC, et al.  Cytosine arabinoside (ara-C) resistance confers cross-resistance or collateral sensitivity to other classes of anti-leukemic drugs. Anticancer Res. 2000;20:139–150
  39. Månsson E, Liliemark E, Söderhäll S, Gustafsson G, Eriksson S, Albertioni F. Real-time quantitative PCR assays for deoxycytidine kinase, deoxyguanosine kinase and 5′-nucleotidase mRNA measurement in cell lines and in patients with leukemia. Leukemia. 2002;16:386–392
  40. Choi CH, Ling V. Isolation and characterization of daunorubicin-resistant AML-2 sublines. Mol Cells. 1997;7:170–177
  41. Urasaki Y, Ueda T, Yoshida A, Fukushima T, Takeuchi N, Tsuruo T, et al.  Establishment of a daunorubicin-resistant cell line which shows multi-drug resistance by multifactorial mechanisms. Anticancer Res. 1996;16:709–714
  42. Jonsson K, Dahlberg N, Tidefelt U, Paul C, Andersson G. Characterization of an anthracycline-resistant human promyelocyte leukemia (HL-60) cell line with an elevated MDR-1 gene expression. Biochem Pharmacol. 1995;49:755–762
  43. Yanovich S, Hall RE, Gewirtz DA. Characterization of a K562 multidrug-resistant cell line. Cancer Res. 1989;49:4499–4503
  44. Batist G, Schecter R, Woo A, Greene D, Lehnert S. Glutathione depletion in human and in rat multi-drug resistant breast cancer cell lines. Biochem Pharmacol. 1991;41:631–635
  45. Benderra Z, Trussardi A, Morjani H, Villa AM, Doglia SM, Manfait M. Regulation of cellular glutathione modulates nuclear accumulation of daunorubicin in human MCF7 cells overexpressing multidrug resistance associated protein. Eur J Cancer. 2000;36:428–434
  46. Knaust E, Porwit-MacDonald A, Gruber A, Xu D, Peterson C. Heterogeneity of isolated mononuclear cells from patients with acute myeloid leukemia affects cellular accumulation and efflux of daunorubicin. Haematologica. 2000;85:124–132
  47. Roovers DJ, van Vliet M, Bloem AC, Lokhorst HM. Idarubicin overcomes P-glycoprotein-related multidrug resistance: comparison with doxorubicin and daunorubicin in human multiple myeloma cell lines. Leuk Res. 1999;23:539–548
  48. Takemura H, Urasaki Y, Yoshida A, Fukushima T, Ueda T. Simultaneous treatment with 1-beta-D-arabinofuranosylcytosine and daunorubicin induces cross-resistance to both drugs due to a combination-specific mechanism in HL60 cells. Cancer Res. 2001;61:172–177

PII: S0145-2126(02)00224-2

doi: 10.1016/S0145-2126(02)00224-2

Leukemia Research
Volume 27, Issue 5 , Pages 445-453 , May 2003

Article Tools

* Image Usage & Resolution